stockrow
Friday 6 November 2026
Export CSBR’s income statement to Excel — free account
Champions Oncology, Inc.
CSBR Healthcare Biotechnology
Champions Oncology, Inc.’s revenue for fiscal 2026 (year ended April 2026) was $59.4 million, up 4.36% from fiscal 2025.
- Revenue
- +8.84%
- EPS
- 0.00%
- Free cash flow
- −198.7%
Quarter to July 2026, against a year earlier
4.80
0.04
+0.84%
Follow CSBR
Alert me
| Older periods | Oct '25 | Jan '26 | Apr '26 | Jul '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
36.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
1.61 | 1.71 | 1.39 | 1.23 | |
P/FCF ratio |
16.73 | 25.79 | 0.00 | 0.00 | |
P/Operating CF |
(54.37) | (73.95) | (41.26) | (151.41) | |
P/B ratio |
22.30 | 22.62 | 20.27 | 16.70 | |
Price to Tangible BV |
24.21 | 24.49 | 22.08 | 18.06 | |
EV/Sales |
1.47 | 1.59 | 1.31 | 1.16 | |
EV/EBITDA |
23.49 | 0.00 | 327.69 | 225.82 | |
EV/Operating CF |
13.81 | 20.93 | (17.37) | (12.62) | |
EV/FCF |
15.23 | 23.96 | (15.50) | (11.49) | |
Quick Ratio |
0.91 | 0.93 | 0.91 | 0.96 | |
Current Ratio |
0.96 | 0.98 | 0.96 | 1.03 | |
Net Debt/EBITDA |
(15.71) | (109.65) | 24.24 | 45.87 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
2.11 | 1.96 | 2.00 | 1.90 | |
Operating CF/Net income |
(6.47) | 4.80 | 2.86 | 1.15 | |
Capex/Depreciation |
(0.68) | (0.04) | (0.74) | (0.18) | |
Research and Development Expense of Revenue |
17.40% | 13.71% | 15.29% | 15.39% | |
Selling, General and Administrative Expense of Revenue |
33.07% | 34.07% | 39.26% | 37.83% | |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.01 | 0.01 | |
Share Based Compensation of Revenue |
1.66% | 2.55% | 2.58% | 5.03% | |
Graham Net Nets |
(0.05) | (0.04) | (0.04) | (0.13) | |
Graham Number |
1.15 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
2.78% | (2.24%) | (1.34%) | (1.49%) | |
Free Cash Flow Yield |
5.98% | 3.88% | (6.08%) | (8.21%) | |
Revenue per Share |
1.09 | 1.19 | 1.00 | 1.10 | |
Operating CF per Share |
(0.13) | (0.10) | (0.14) | (0.04) | |
Capex per Share |
(0.02) | 0.00 | (0.02) | 0.00 | |
Free Cash Flow per Share |
(0.14) | (0.10) | (0.16) | (0.04) | |
Cash per Share |
0.62 | 0.51 | 0.35 | 0.31 | |
Shareholders Equity per Share |
0.31 | 0.32 | 0.29 | 0.32 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.31 | 0.32 | 0.29 | 0.32 | |
Free Cash Flow |
(1.98) | (1.35) | (2.24) | (0.55) | |
Working Capital |
(0.81) | (0.49) | (0.70) | 0.56 | |
Capital Expenditures |
(0.24) | (0.01) | (0.24) | (0.05) | |
Net Current Asset Value |
(4.60) | (3.88) | (3.70) | (9.54) | |
EV/EBIT |
39.96 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.00 | 0.02 | 0.00 | |
Price to Operating Income |
43.88 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
11.00 | 13.92 | 12.19 | 11.54 | |
Average Payables |
5.42 | 5.41 | 5.58 | 5.24 | |
Average Assets |
27.70 | 29.54 | 29.67 | 31.92 | |
Average Common Equity |
2.46 | 4.92 | 3.92 | 4.00 |
Columns are period end dates